Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma

Shogo Okazaki, Kiyoko Umene, Juntaro Yamasaki, Kentaro Suina, Yuji Otsuki, Momoko Yoshikawa, Yushi Minami, Takashi Masuko, Sho Kawaguchi, Hideki Nakayama, Kouji Banno, Daisuke Aoki, Hideyuki Saya, Osamu Nagano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Targeting the function of membrane transporters in cancer stemlike cells is a potential new therapeutic approach. Cystine-glutamate antiporter xCT expressed in CD44 variant (CD44v)-expressing cancer cells contributes to the resistance to oxidative stress as well as cancer therapy through promoting glutathione (GSH)-mediated antioxidant defense. Amino acid transport by xCT might, thus, be a promising target for cancer treatment, whereas the determination factors for cancer cell sensitivity to xCT-targeted therapy remain unclear. Here, we demonstrate that high expression of xCT and glutamine transporter ASCT2 is correlated with undifferentiated status and diminished along with cell differentiation in head and neck squamous cell carcinoma (HNSCC). The cytotoxicity of the xCT inhibitor sulfasalazine relies on ASCT2-dependent glutamine uptake and glutamate dehydrogenase (GLUD)-mediated α-ketoglutarate (α-KG) production. Metabolome analysis revealed that sulfasalazine treatment triggers the increase of glutamate-derived tricarboxylic acid cycle intermediate α-KG, in addition to the decrease of cysteine and GSH content. Furthermore, ablation of GLUD markedly reduced the sulfasalazine cytotoxicity in CD44v-expressing stemlike HNSCC cells. Thus, xCT inhibition by sulfasalazine leads to the impairment of GSH synthesis and enhancement of mitochondrial metabolism, leading to reactive oxygen species (ROS) generation and, thereby, triggers oxidative damage. Our findings establish a rationale for the use of glutamine metabolism (glutaminolysis)-related genes, including ASCT2 and GLUD, as biomarkers to predict the efficacy of xCT-targeted therapy for heterogeneous HNSCC tumors.

Original languageEnglish
Pages (from-to)3453-3463
Number of pages11
JournalCancer science
Volume110
Issue number11
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Sulfasalazine
Glutamate Dehydrogenase
Glutamine
Genes
Neoplasms
Glutamic Acid
Therapeutics
Antiporters
Cystine
Citric Acid Cycle
Membrane Transport Proteins
Metabolome
Glutathione
Cysteine
Carcinoma, squamous cell of head and neck
Cell Differentiation
Reactive Oxygen Species
Oxidative Stress
Antioxidants
Biomarkers

Keywords

  • ASCT2
  • CD44 variant
  • glutamate dehydrogenase
  • head and neck cancer
  • xCT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma. / Okazaki, Shogo; Umene, Kiyoko; Yamasaki, Juntaro; Suina, Kentaro; Otsuki, Yuji; Yoshikawa, Momoko; Minami, Yushi; Masuko, Takashi; Kawaguchi, Sho; Nakayama, Hideki; Banno, Kouji; Aoki, Daisuke; Saya, Hideyuki; Nagano, Osamu.

In: Cancer science, Vol. 110, No. 11, 01.11.2019, p. 3453-3463.

Research output: Contribution to journalArticle

Okazaki, S, Umene, K, Yamasaki, J, Suina, K, Otsuki, Y, Yoshikawa, M, Minami, Y, Masuko, T, Kawaguchi, S, Nakayama, H, Banno, K, Aoki, D, Saya, H & Nagano, O 2019, 'Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma', Cancer science, vol. 110, no. 11, pp. 3453-3463. https://doi.org/10.1111/cas.14182
Okazaki, Shogo ; Umene, Kiyoko ; Yamasaki, Juntaro ; Suina, Kentaro ; Otsuki, Yuji ; Yoshikawa, Momoko ; Minami, Yushi ; Masuko, Takashi ; Kawaguchi, Sho ; Nakayama, Hideki ; Banno, Kouji ; Aoki, Daisuke ; Saya, Hideyuki ; Nagano, Osamu. / Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma. In: Cancer science. 2019 ; Vol. 110, No. 11. pp. 3453-3463.
@article{5492be47fc5d4a50bf2056b8fd3efcbd,
title = "Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma",
abstract = "Targeting the function of membrane transporters in cancer stemlike cells is a potential new therapeutic approach. Cystine-glutamate antiporter xCT expressed in CD44 variant (CD44v)-expressing cancer cells contributes to the resistance to oxidative stress as well as cancer therapy through promoting glutathione (GSH)-mediated antioxidant defense. Amino acid transport by xCT might, thus, be a promising target for cancer treatment, whereas the determination factors for cancer cell sensitivity to xCT-targeted therapy remain unclear. Here, we demonstrate that high expression of xCT and glutamine transporter ASCT2 is correlated with undifferentiated status and diminished along with cell differentiation in head and neck squamous cell carcinoma (HNSCC). The cytotoxicity of the xCT inhibitor sulfasalazine relies on ASCT2-dependent glutamine uptake and glutamate dehydrogenase (GLUD)-mediated α-ketoglutarate (α-KG) production. Metabolome analysis revealed that sulfasalazine treatment triggers the increase of glutamate-derived tricarboxylic acid cycle intermediate α-KG, in addition to the decrease of cysteine and GSH content. Furthermore, ablation of GLUD markedly reduced the sulfasalazine cytotoxicity in CD44v-expressing stemlike HNSCC cells. Thus, xCT inhibition by sulfasalazine leads to the impairment of GSH synthesis and enhancement of mitochondrial metabolism, leading to reactive oxygen species (ROS) generation and, thereby, triggers oxidative damage. Our findings establish a rationale for the use of glutamine metabolism (glutaminolysis)-related genes, including ASCT2 and GLUD, as biomarkers to predict the efficacy of xCT-targeted therapy for heterogeneous HNSCC tumors.",
keywords = "ASCT2, CD44 variant, glutamate dehydrogenase, head and neck cancer, xCT",
author = "Shogo Okazaki and Kiyoko Umene and Juntaro Yamasaki and Kentaro Suina and Yuji Otsuki and Momoko Yoshikawa and Yushi Minami and Takashi Masuko and Sho Kawaguchi and Hideki Nakayama and Kouji Banno and Daisuke Aoki and Hideyuki Saya and Osamu Nagano",
year = "2019",
month = "11",
day = "1",
doi = "10.1111/cas.14182",
language = "English",
volume = "110",
pages = "3453--3463",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma

AU - Okazaki, Shogo

AU - Umene, Kiyoko

AU - Yamasaki, Juntaro

AU - Suina, Kentaro

AU - Otsuki, Yuji

AU - Yoshikawa, Momoko

AU - Minami, Yushi

AU - Masuko, Takashi

AU - Kawaguchi, Sho

AU - Nakayama, Hideki

AU - Banno, Kouji

AU - Aoki, Daisuke

AU - Saya, Hideyuki

AU - Nagano, Osamu

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Targeting the function of membrane transporters in cancer stemlike cells is a potential new therapeutic approach. Cystine-glutamate antiporter xCT expressed in CD44 variant (CD44v)-expressing cancer cells contributes to the resistance to oxidative stress as well as cancer therapy through promoting glutathione (GSH)-mediated antioxidant defense. Amino acid transport by xCT might, thus, be a promising target for cancer treatment, whereas the determination factors for cancer cell sensitivity to xCT-targeted therapy remain unclear. Here, we demonstrate that high expression of xCT and glutamine transporter ASCT2 is correlated with undifferentiated status and diminished along with cell differentiation in head and neck squamous cell carcinoma (HNSCC). The cytotoxicity of the xCT inhibitor sulfasalazine relies on ASCT2-dependent glutamine uptake and glutamate dehydrogenase (GLUD)-mediated α-ketoglutarate (α-KG) production. Metabolome analysis revealed that sulfasalazine treatment triggers the increase of glutamate-derived tricarboxylic acid cycle intermediate α-KG, in addition to the decrease of cysteine and GSH content. Furthermore, ablation of GLUD markedly reduced the sulfasalazine cytotoxicity in CD44v-expressing stemlike HNSCC cells. Thus, xCT inhibition by sulfasalazine leads to the impairment of GSH synthesis and enhancement of mitochondrial metabolism, leading to reactive oxygen species (ROS) generation and, thereby, triggers oxidative damage. Our findings establish a rationale for the use of glutamine metabolism (glutaminolysis)-related genes, including ASCT2 and GLUD, as biomarkers to predict the efficacy of xCT-targeted therapy for heterogeneous HNSCC tumors.

AB - Targeting the function of membrane transporters in cancer stemlike cells is a potential new therapeutic approach. Cystine-glutamate antiporter xCT expressed in CD44 variant (CD44v)-expressing cancer cells contributes to the resistance to oxidative stress as well as cancer therapy through promoting glutathione (GSH)-mediated antioxidant defense. Amino acid transport by xCT might, thus, be a promising target for cancer treatment, whereas the determination factors for cancer cell sensitivity to xCT-targeted therapy remain unclear. Here, we demonstrate that high expression of xCT and glutamine transporter ASCT2 is correlated with undifferentiated status and diminished along with cell differentiation in head and neck squamous cell carcinoma (HNSCC). The cytotoxicity of the xCT inhibitor sulfasalazine relies on ASCT2-dependent glutamine uptake and glutamate dehydrogenase (GLUD)-mediated α-ketoglutarate (α-KG) production. Metabolome analysis revealed that sulfasalazine treatment triggers the increase of glutamate-derived tricarboxylic acid cycle intermediate α-KG, in addition to the decrease of cysteine and GSH content. Furthermore, ablation of GLUD markedly reduced the sulfasalazine cytotoxicity in CD44v-expressing stemlike HNSCC cells. Thus, xCT inhibition by sulfasalazine leads to the impairment of GSH synthesis and enhancement of mitochondrial metabolism, leading to reactive oxygen species (ROS) generation and, thereby, triggers oxidative damage. Our findings establish a rationale for the use of glutamine metabolism (glutaminolysis)-related genes, including ASCT2 and GLUD, as biomarkers to predict the efficacy of xCT-targeted therapy for heterogeneous HNSCC tumors.

KW - ASCT2

KW - CD44 variant

KW - glutamate dehydrogenase

KW - head and neck cancer

KW - xCT

UR - http://www.scopus.com/inward/record.url?scp=85073774917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073774917&partnerID=8YFLogxK

U2 - 10.1111/cas.14182

DO - 10.1111/cas.14182

M3 - Article

C2 - 31444923

AN - SCOPUS:85073774917

VL - 110

SP - 3453

EP - 3463

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -